Actively Recruiting
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
Led by The University of Hong Kong · Updated on 2026-05-14
980
Participants Needed
1
Research Sites
140 weeks
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
T
The Family Planning Association of Hong Kong
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare the failure rate of the levonorgestrel (LNG)-piroxicam combination regimen versus ulipristal acetate (UPA) as emergency contraception (EC). The main questions it aims to answer are: 1. whether the LNG-piroxicam combination regimen has a lower failure rate than UPA for EC; 2. whether the LNG-piroxicam combination regimen has a higher percentage of pregnancies prevented than UPA for EC 3. whether there is any difference in the change in the subsequent menstrual cycle and adverse effect profile between the two regimens Participants will: 1. Take a single dose of either (i) LNG 1.5 mg plus piroxicam 40 mg and a placebo tablet resembling UPA, or (ii) UPA 30 mg plus placebo tablets resembling LNG and piroxicam. 2. Have a blood test for serum LH, oestradiol an progesterone. 3. Keep a diary of their vaginal bleeding episodes, adverse effects symptoms, any further acts of intercourse and the type of contraception used. 4. Have a follow-up either in person by phone about 1-2 weeks after the next expected menstruation. 5. If normal menstrual bleeding has not occurred by that time, a pregnancy test will be carried out.
CONDITIONS
Official Title
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 45 years
- Requesting oral emergency contraception within 120 hours of a single or first unprotected intercourse in the current menstrual cycle
- Available for follow-up over the next 6 weeks
You will not qualify if you...
- Post-abortion or postpartum with menstruation not yet returned
- Currently taking anticoagulants, cyclosporine, tacrolimus, corticosteroids, lithium, SSRIs, or quinolones
- More than 120 hours since unprotected intercourse in this cycle
- Pregnant at time of presentation
- Breastfeeding
- Sterilized or partner sterilized, or having an intrauterine contraceptive device
- Uncertain about date of last menstrual period
- Used hormonal contraceptive, progestogen medication, or NSAID in the past week
- History of asthma, urticaria, or allergic reactions to piroxicam, aspirin, or other NSAIDs
- History of ischemic heart disease, heart failure, hypertension, cerebrovascular disease, or kidney failure requiring dialysis
- History of peptic ulcer disease or gastrointestinal bleeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Family Planning Association of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
R
Raymond Hang Wun Li, MD, FRCOG
CONTACT
S
Sue Seen Tsing Lo, MD, FRCOG
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here